IPP Bureau
Zydus receives USFDA final approval for chlorpromazine hydrochloride injection
By IPP Bureau - March 14, 2024
Chlorpromazine Hydrochloride Injection is used to treat certain mental/mood disorders
Merck plans to conduct clinical trials of a novel investigational HPV vaccine for GARDASIL9
By IPP Bureau - March 14, 2024
Company reaffirms commitment to reduce the global burden of HPV-related diseases, including certain cancers
Nirma acquires majority stake in Glenmark Life Sciences
By IPP Bureau - March 13, 2024
Completes acquisition of 75% of share capital from Glenmark Pharmaceuticals
Jubilant Ingrevia partners with O2 Renewable to increase use of green energy
By IPP Bureau - March 13, 2024
This partnership marks a significant step for the Company towards establishing renewable energy power generation using hybrid open excess through solar and wind sources
Evonik establishes a new research institute dedicated to skin sciences
By IPP Bureau - March 13, 2024
New institute brings together Evonik’s most advanced biotech platform and a global network of evaluation labs
Healthcare Triangle appoints Anand Kumar as Interim CEO
By IPP Bureau - March 13, 2024
Anand is committed to leading the company's continued commitment to driving innovation in Health Care through the utilization of Digital transformation, AI and LLM
European Commission approves Pfizer’s Prevenar 20 to help protect infants and children against pneumococcal disease
By IPP Bureau - March 13, 2024
PREVENAR offers the broadest serotype coverage of any pediatric pneumococcal conjugate vaccine to help protect infants and children from the 20 serotypes responsible for the majority of currently circulating pneumococcal disease in the EU and globally
Dr Mandaviya launches Credit Assistance Program for Jan Aushadhi Kendras
By IPP Bureau - March 13, 2024
From only 80 Jan Aushadhi Kendras in 2014, there are around 11,000 units operating across the country today
Venus Remedies gets huge global acclaim with UNICEF GMP approval
By IPP Bureau - March 12, 2024
Venus Remedies' manufacturing unit, located in Baddi, Himachal Pradesh, has been recommended for supplying cephalosporin dry powder to UNICEF
Merck completes acquisition of Harpoon Therapeutics
By IPP Bureau - March 12, 2024
Acquisition broadens oncology pipeline with a portfolio of novel T-cell engagers including HPN328 (MK-6070), an investigational delta-like ligand 3 (DLL3) targeting T-cell engager
Successful use of Zidebactam/Cefepime to treat skull bone infection & pneumonia caused by extreme-drug resistant pseudomonas
By IPP Bureau - March 12, 2024
With just few days of treatment, the patient started responding well and finally complete clinical resolution of infection was attained
AstraZeneca Pharma India, Mankind Pharma ink pact to distribute asthma medicine
By IPP Bureau - March 12, 2024
India is contributing 13% to the global asthma burden and a disproportionate 43% of the global asthma deaths.
USFDA grants orphan drug and pediatric exclusivities for Cresemba for aspergillosis and mucormycosis in children
By IPP Bureau - March 12, 2024
CRESEMBA receives seven years and six months of US market exclusivity for these pediatric indications
Pfizer announces positive Phase 3 trial of ADCETRIS regimen in patients with DLBCL
By IPP Bureau - March 12, 2024
Pfizer to discuss regulatory submission with FDA, potentially leading to eighth indication for ADCETRIS
